Core Insights - Optimi Health's psilocybin capsules have been included in Medibank's AUD $10 million psychotherapy program for Treatment-Resistant Depression (TRD) [2][3][4] - Medibank, Australia's largest private health insurer, previously funded MDMA-assisted therapy for PTSD and is now expanding its coverage to include psilocybin [4][6] - The inclusion of psilocybin reflects a strategic shift towards supporting innovative mental health therapies [6][7] Company Overview - Optimi Health Corp. is a Canadian GMP-compliant manufacturer of MDMA and psilocybin, licensed by Health Canada [3][9] - The company operates from two facilities in British Columbia and supplies active pharmaceutical ingredients and finished dosage forms [9][10] - Optimi's psilocybin capsules became available in Australia on September 3, 2025, under the Authorized Prescriber Scheme [6][10] Industry Context - The Medibank psychotherapy program is part of a broader AUD $50 million initiative aimed at improving mental health access and innovation over five years [6] - The growing acceptance of psychedelic medicines in insured mental health care indicates a shift in treatment paradigms for conditions like TRD and PTSD [7]